Stocktoria
INCYTE CORP INCY
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research · website · IPO 1993-12-06
INCYTE CORP financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.1B | $4.2B | $3.7B | $3.4B | $3.0B |
| R&D expense | $2.1B | $2.6B | $1.6B | $1.6B | $1.5B |
| SG&A expense | $1.4B | $1.2B | $1.2B | $1.0B | $739.6M |
| Operating income | $1.5B | $61.4M | $620.5M | $579.4M | $585.8M |
| Interest expense | — | — | $2.6M | $2.7M | $1.9M |
| Income tax | $377.8M | $284.0M | $236.6M | $188.5M | -$378.1M |
| Net income | $1.3B | $32.6M | $597.6M | $340.7M | $948.6M |
| EPS (diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
| Operating cash flow | $1.4B | $335.3M | $496.5M | $969.9M | $749.5M |
| Cash & equivalents | $3.1B | $1.7B | $3.2B | $3.0B | $2.1B |
| Inventory | $101.1M | $58.9M | $63.0M | $42.0M | $27.9M |
| Total assets | $7.0B | $5.4B | $6.8B | $5.8B | $4.9B |
| Total liabilities | $1.8B | $2.0B | $1.6B | $1.5B | $1.2B |
| Shareholders' equity | $5.2B | $3.4B | $5.2B | $4.4B | $3.8B |
Source: SEC EDGAR filings · CIK 0000879169 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.